AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Mindset disagrees with and denies the allegations set forth from Reunion.
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Subscribe To Our Newsletter & Stay Updated